Orbifloxacin
(right click,save link as to download,it is a temp file,please download as soon as possible, you can also use CTRL+S to save the whole html page)
Basic Info
| Common Name | Orbifloxacin(F05749) |
| 2D Structure | |
| FRCD ID | F05749 |
| CAS Number | 113617-63-3 |
| PubChem CID | 60605 |
| Formula | C19H20F3N3O3 |
| IUPAC Name | 1-cyclopropyl-7-[(3S,5R)-3,5-dimethylpiperazin-1-yl]-5,6,8-trifluoro-4-oxoquinoline-3-carboxylic acid |
| InChI Key | QIPQASLPWJVQMH-DTORHVGOSA-N |
| InChI | InChI=1S/C19H20F3N3O3/c1-8-5-24(6-9(2)23-8)17-14(21)13(20)12-16(15(17)22)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6H2,1-2H3,(H,27,28)/t8-,9+ |
| Canonical SMILES | CC1CN(CC(N1)C)C2=C(C3=C(C(=C2F)F)C(=O)C(=CN3C4CC4)C(=O)O)F |
| Isomeric SMILES | C[C@@H]1CN(C[C@@H](N1)C)C2=C(C3=C(C(=C2F)F)C(=O)C(=CN3C4CC4)C(=O)O)F |
| Synonyms |
1-cyclopropyl-7-((3S,5R)-3,5-dimethylpiperazin-1-yl)-5,6,8-trifluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
ORBIFLOXACIN
113617-63-3
Orbax
UNII-660932TPY6
660932TPY6
NCGC00160518-01
DSSTox_CID_26201
DSSTox_RID_81432
DSSTox_GSID_46201
|
| Classifies |
Predicted: Veterinary Drug
|
| Update Date | Nov 13, 2018 17:07 |
Chemical Taxonomy
| Kingdom | Organic compounds |
| Superclass | Organoheterocyclic compounds |
| Class | Quinolines and derivatives |
| Subclass | Quinoline carboxylic acids |
| Intermediate Tree Nodes | Not available |
| Direct Parent | Quinoline carboxylic acids |
| Alternative Parents |
|
| Molecular Framework | Aromatic heteropolycyclic compounds |
| Substituents | Quinoline-3-carboxylic acid - Fluoroquinolone - N-arylpiperazine - Aminoquinoline - Haloquinoline - Dihydroquinolone - Dihydroquinoline - Pyridine carboxylic acid - Pyridine carboxylic acid or derivatives - Dialkylarylamine - Tertiary aliphatic/aromatic amine - Benzenoid - Aryl fluoride - Pyridine - Aryl halide - Piperazine - 1,4-diazinane - Vinylogous amide - Vinylogous halide - Heteroaromatic compound - Tertiary amine - Amino acid - Amino acid or derivatives - Azacycle - Secondary amine - Carboxylic acid derivative - Carboxylic acid - Secondary aliphatic amine - Monocarboxylic acid or derivatives - Organic oxygen compound - Organooxygen compound - Hydrocarbon derivative - Organic nitrogen compound - Organopnictogen compound - Organic oxide - Amine - Organohalogen compound - Organofluoride - Organonitrogen compound - Aromatic heteropolycyclic compound |
| Description | This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions. |
Properties
| Property Name | Property Value |
|---|---|
| Molecular Weight | 395.382 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 3 |
| Complexity | 691 |
| Monoisotopic Mass | 395.146 |
| Exact Mass | 395.146 |
| XLogP | 0.9 |
| Formal Charge | 0 |
| Heavy Atom Count | 28 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Isotope Atom Count | 0 |
| Covalently-Bonded Unit Count | 1 |
ADMET
| Model | Result | Probability |
|---|---|---|
| Absorption | ||
| Blood-Brain Barrier | BBB- | 0.9767 |
| Human Intestinal Absorption | HIA+ | 0.9824 |
| Caco-2 Permeability | Caco2+ | 0.8335 |
| P-glycoprotein Substrate | Substrate | 0.8147 |
| P-glycoprotein Inhibitor | Non-inhibitor | 0.8774 |
| Non-inhibitor | 0.8229 | |
| Renal Organic Cation Transporter | Non-inhibitor | 0.8090 |
| Distribution | ||
| Subcellular localization | Lysosome | 0.6023 |
| Metabolism | ||
| CYP450 2C9 Substrate | Non-substrate | 0.8430 |
| CYP450 2D6 Substrate | Non-substrate | 0.8884 |
| CYP450 3A4 Substrate | Non-substrate | 0.6356 |
| CYP450 1A2 Inhibitor | Non-inhibitor | 0.8199 |
| CYP450 2C9 Inhibitor | Non-inhibitor | 0.8246 |
| CYP450 2D6 Inhibitor | Non-inhibitor | 0.9001 |
| CYP450 2C19 Inhibitor | Non-inhibitor | 0.8252 |
| CYP450 3A4 Inhibitor | Non-inhibitor | 0.8325 |
| CYP Inhibitory Promiscuity | Low CYP Inhibitory Promiscuity | 0.6425 |
| Excretion | ||
| Toxicity | ||
| Human Ether-a-go-go-Related Gene Inhibition | Weak inhibitor | 0.9433 |
| Non-inhibitor | 0.7847 | |
| AMES Toxicity | AMES toxic | 0.6221 |
| Carcinogens | Non-carcinogens | 0.8088 |
| Fish Toxicity | High FHMT | 0.9931 |
| Tetrahymena Pyriformis Toxicity | High TPT | 0.9316 |
| Honey Bee Toxicity | Low HBT | 0.8932 |
| Biodegradation | Not ready biodegradable | 1.0000 |
| Acute Oral Toxicity | III | 0.7770 |
| Carcinogenicity (Three-class) | Non-required | 0.5540 |
| Model | Value | Unit |
|---|---|---|
| Absorption | ||
| Aqueous solubility | -3.6133 | LogS |
| Caco-2 Permeability | 1.1068 | LogPapp, cm/s |
| Distribution | ||
| Metabolism | ||
| Excretion | ||
| Toxicity | ||
| Rat Acute Toxicity | 1.9492 | LD50, mol/kg |
| Fish Toxicity | 1.3069 | pLC50, mg/L |
| Tetrahymena Pyriformis Toxicity | 0.5740 | pIGC50, ug/L |
MRLs
| Food | Product Code | Country | MRLs | Application Date | Notes |
|---|---|---|---|---|---|
| Milk | Japan | 0.02ppm | |||
| Pig,Edible Offal | Japan | 0.02ppm | |||
| Cattle,Edible Offal | Japan | 0.02ppm | |||
| Pig,Kidney | Japan | 0.02ppm | |||
| Cattle,Kidney | Japan | 0.02ppm | |||
| Pig,Liver | Japan | 0.02ppm | |||
| Cattle,Liver | Japan | 0.02ppm | |||
| Pig,Fat | Japan | 0.02ppm | |||
| Cattle,Fat | Japan | 0.02ppm | |||
| Pig,Muscle | Japan | 0.02ppm | |||
| Cattle,Muscle | Japan | 0.02ppm |
References
| Title | Journal | Date | Pubmed ID |
|---|---|---|---|
| Development of a novel genetically modified bioluminescent-bacteria-based assayfor detection of fluoroquinolones in animal-derived foods. | Anal Bioanal Chem | 2014 Dec | 25354889 |
| Mixed immunoassay design for multiple chemical residues detection. | Anal Bioanal Chem | 2013 Apr | 23380954 |
| Amino acid substitutions in GyrA and ParC are associated with fluoroquinoloneresistance in Mycoplasma bovis isolates from Japanese dairy calves. | J Vet Med Sci | 2013 | 23503166 |
| Rapid screening method for quinolone residues in livestock and fishery productsusing immobilised metal chelate affinity chromatographic clean-up and liquidchromatography-fluorescence detection. | Food Addit Contam Part A Chem Anal Control Expo Risk Assess | 2011Sep | 21749230 |
| Pharmacokinetic-pharmacodynamic integration of orbifloxacin in Japanese quail(Coturnix japonica) following oral and intravenous administration. | J Vet Pharmacol Ther | 2011 Aug | 20950349 |
| Quantitation of fluoroquinolones in honey using tandem mass spectrometry(LC-MS/MS): nested validation with two mass spectrometers. | J AOAC Int | 2010 Sep-Oct | 21140677 |
| Short communication: Fluoroquinolone susceptibility of Staphylococcus aureusstrains isolated from caprine clinical mastitis in southeast Spain. | J Dairy Sci | 2010 Nov | 20965339 |
| Rapid determination of fluoroquinolone residues in honey by a microbiologicalscreening method and liquid chromatography. | J AOAC Int | 2010 Jul-Aug | 20922969 |
| Single-step extraction followed by LC for determination of (fluoro)quinolone drugresidues in muscle, eggs, and milk. | J Sep Sci | 2010 Apr | 20175091 |
| Approaches for application of sub and supercritical fluid extraction forquantification of orbifloxacin from plasma and milk: application to dispositionkinetics. | Anal Chim Acta | 2009 Jan 5 | 19046687 |
| Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes. | J Vet Pharmacol Ther | 2009 Aug | 19614838 |
| Pharmacokinetics and milk penetration of orbifloxacin after intravenous,subcutaneous, and intramuscular administration to lactating goats. | J Dairy Sci | 2007 Sep | 17699040 |
| [Determination of 16 quinolone residues in animal tissues using high performance liquid chromatography coupled with electrospray ionization tandem massspectrometry]. | Se Pu | 2007 Jul | 17970104 |
| Multiresidue determination of fluoroquinolones in shrimp by liquidchromatography-fluorescence-mass spectrometry. | J AOAC Int | 2005 Jul-Aug | 16152936 |